Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Convertible Debt: 2020-2025

Historic Convertible Debt for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $93.1 million.

  • Pharming Group N.V's Convertible Debt rose 1.13% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 1.13%. This contributed to the annual value of $136.6 million for FY2023, which is 3.78% up from last year.
  • Latest data reveals that Pharming Group N.V reported Convertible Debt of $93.1 million as of Q3 2025, which was up 2.05% from $91.3 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Convertible Debt registered a high of $145.4 million during Q2 2021, and its lowest value of $120,005 during Q3 2022.
  • Its 3-year average for Convertible Debt is $111.7 million, with a median of $111.4 million in 2023.
  • Per our database at Business Quant, Pharming Group N.V's Convertible Debt tumbled by 99.91% in 2022 and then surged by 108,006.33% in 2023.
  • Over the past 5 years, Pharming Group N.V's Convertible Debt (Quarterly) stood at $139.0 million in 2021, then fell by 5.32% to $131.6 million in 2022, then rose by 3.78% to $136.6 million in 2023, then decreased by 29.01% to $92.1 million in 2024, then climbed by 1.13% to $93.1 million in 2025.
  • Its Convertible Debt was $93.1 million in Q3 2025, compared to $91.3 million in Q2 2025 and $83.8 million in Q1 2025.